Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Amgen pays Arrowhead $20 million milestone for start of Phase 2 study of AMG 890 formerly ARO-LPA

Click to view original post